The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Combination Therapy in Type 2 Diabetes

제2형 당뇨병의 병합요법

  • Bae, Hak-Yeon (Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University Hospital)
  • 배학연 (조선대학교병원 내분비대사내과)
  • Published : 2011.06.01
⟨ Previous Next ⟩

Abstract

Managing type 2 diabetes has become more complex as pharmacotherapy has expanded. Therapies for type 2 diabetes can be divided into drugs facilitating supply of endogenous insulin or those enhancing insulin actions. Successful treatment of type 2 diabetes combines approaches to lifestyle modification frequently in conjunction with use of pharmacologic therapy. The dual aspects of type 2 diabetes, insulin resistance and insulin deficiency, are important factors in therapy selection and the subsequent reponse to therapy. Most patients have gradually increasing needs for additional therapy. Some patients require combination pharmacologic therapy at the time of initial treatment, especially if they have a markedly elevated HbA1c. We describes combination pharmacologic therapy in type 2 diabetes, recent evidence and opinions on sequences for type 2 diabetes.

Keywords

References

  1. 대한당뇨병학회 진료지침 Task Force Team. 약물치료-경구혈당강하제. 당뇨병 진료지침 2007:60-65.
  2. 김응진, 민헌기, 최영길 등. 당뇨병학. 제3판. 대한당뇨병학회 2005:245-251.
  3. United Kingdom Prospective Diabetes Study Group (UKPDS). 13: relative efficacy of randomly allocated diet, sulphonylureas, insulin, or metformin in patients with newly diagnosed noninsulin- dependent diabetes followed for three years. BMJ 1995; 310:83-88. https://doi.org/10.1136/bmj.310.6972.83
  4. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin 2007;23:945-952. https://doi.org/10.1185/030079907X178766
  5. Van Gaal LF, De Leeuw IH. Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia 2003;46(Suppl 1):M44-M50. https://doi.org/10.1007/s00125-002-0936-0
  6. Charpentier G. Oral combination therapy for type 2 diabetes. Diabetes Metab Res Rev 2002;18(Suppl 3):S70-S76. https://doi.org/10.1002/dmrr.278
  7. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-1702. https://doi.org/10.1001/jama.283.13.1695
  8. Giorgino F, Laviola L, Leonardini A. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes Res Clin Pract 2005;68(Suppl 1):S22-S29. https://doi.org/10.1016/j.diabres.2005.03.012
  9. Massi-Benedetti M, Orsini-Federici M. Treatment of type 2 diabetes with combined therapy: what are the pros and cons? Diabetes Care 2008;31(Suppl 2):S131-S135. https://doi.org/10.2337/dc08-s233
  10. Richard IG, Holt, Clive SC, Allan F, Barry JG. Diabetes. 4th ed. Wiley-Blackwell, 2010.
  11. Keating GM. Vildagliptin: a review of its use in type 2 diabetes mellitus. Drugs 2010;70:2089-2112. https://doi.org/10.2165/11206370-000000000-00000
  12. Charbonnel B, Karasik A, Liu J, Wu M, Meninger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-2643. https://doi.org/10.2337/dc06-0706
  13. Davies M. Nateglinide: better post-prandial glucose control. Prescriber 2002;13:17-27.
  14. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999;22:960-964. https://doi.org/10.2337/diacare.22.6.960
  15. Bailey CJ, Day C. Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 2009;11:527-533. https://doi.org/10.1111/j.1463-1326.2008.00993.x
  16. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 1995;333:541-549. https://doi.org/10.1056/NEJM199508313330902
  17. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low dose rosiglitazone to sulphonylurea therapy improves glycemic control in type 2 diabetic patients. Diabet Med 2000;17:40-47. https://doi.org/10.1046/j.1464-5491.2000.00224.x
  18. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10-17.
  19. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study: the Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-1409. https://doi.org/10.1016/S0149-2918(00)83039-8
  20. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-1702. https://doi.org/10.1001/jama.283.13.1695
  21. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303. https://doi.org/10.7326/0003-4819-131-4-199908170-00008
  22. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-1940. https://doi.org/10.2337/diacare.28.8.1936